
FIG. 1SDS PAGE of RSA-FAB' conjugate



2/9 1608.9 AUC 2771.3 94.3 130.6 3309.3 PK ANALYSIS - Winnonlin RSA-Fab' conjugate --- RSA-Fab' conjugate 39.6 (correction factor) FIG. 2 Pharmacokinetics of RSA-Fab' conjugate or controls in the rat t_{1/2}α 2.6 1.0 -+- Fab'- cys → F(ab')₂ Conjugate Conjugate +- RSA (correction) RSA-Fab' Fab'-cys F(ab')₂ RSA-Fab' 5 8 Time (hours) 0.010-0.100 0.00 1.000 1000.0001 100.000 10.000

% ID x ml total blood volume

 $t_{172}\alpha(h) t_{172}\beta(h)$ AUC $(0-\infty)$ (h*)1g/ml) 780 824 975 NO PK ANALYSIS - Winnonlin 19.5 21.6 0.7 24.7 ND 0.8 £.5 5 2°2 ₽ 2°2 FIG. 3 Pharmacokinetics of RSA-Fab' or Fab'-cys in the rat (assayed by ELISA or cytokine neutralisation RSA-Fab' conjugate RSA-Fab' conjugate RSA-Fab' conjugate igand-albumin) ligand-L chain) ELISA assay. 120 L929 assay: Fab'-cys Fab'-cys . 9 Time (h) 8 7 0.001 0.010 10.000 100.000 1.000. 0.100 1000.0001 [JW/6rl]

FIG. 4 Construction of pPIC (scFv-HSA)





FIG. 5 Reducing SDS PAGE of HSA-scFv fusion proteins

Molecular weights



SUBSTITUTE SHEET (RULE 26)

6/9 (h*%dose) 1163.83 1281.97 AUC(0-∞) 1224.78 1271.6 t₁₇₂B (h) 16.63 15.21 16.48 14.77 t_{1/2}α(h) -- ScFv-UHL-HSA -E-ScFV-G4S-HSA ScFv-HSA 2.28 ScFv-G₄S-HSA 0.98 ScFv-UHL-HSA 3.02 HSA 0.77 PK ANALYSIS --- ScFv-HSA ¥SH-+





FIG. 8Reducing SDS PAGE of HSA-F(ab')₂ conjugate



09/8313

